Recent 8-K filings for IMMX

• May 29, 2026, 5:10 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  Immix Biopharma shareholders elect directors and ratify Crowe LLP as auditor at 2026 annual meeting

  All nine director nominees (including Ilya Rachman, Gabriel Morris, Jason Hsu) elected with over 35M votes each; broker non-votes ~6.4M.

• May 21, 2026, 5:28 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Immix Biopharma prices $150M public offering of 16.8M shares at $8.94

  Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.

• May 21, 2026, 6:04 AM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR

  All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).

• March 30, 2026, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026

  Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.

• March 25, 2026, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 9.01 ◈ Material Agreements

  Immix Biopharma ups ATM offering to $100M from $50M

  Increased max aggregate offering price under ATM agreement from $50M to $100M.

• December 8, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026

  NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.

• December 8, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Immix Biopharma raises ~$93.7M net via 19.1M share and warrant offering at $5.10

  19,117,646 shares at $5.10/share and 490,196 pre-funded warrants at $5.09/warrant in underwritten offering.

• November 26, 2025, 6:59 PM ET other materiality 0.05 neutral item 8.01item 9.01

  Immix Biopharma files updated auditor consents for S-3 registration

  Filed updated consents from former auditor KMJ Corbin and current auditor Crowe LLP, dated Nov 26, 2025.

• September 8, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 5.02item 9.01

  Immix Biopharma raises $9.1M in PIPE; Nancy Chang appointed to board

  Sold 3,831,216 shares at $2.37/share and warrants for 2,873,417 shares at $2.00/share.

• June 23, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Immix Biopharma stockholders elect 8 directors and ratify Crowe LLP as 2025 auditor

  All 8 director nominees elected with 'for' votes ranging from 13.4M to 14.6M; broker non-votes 5.5M across all director proposals.

• June 3, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01

  Immix Biopharma enters ATM equity offering with Citizens JMP Securities

  Agreement allows at-the-market sales of common stock; 3% commission to Agent.

• July 26, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial

  $8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.

• July 22, 2024, 7:59 PM ET other materiality 0.20 neutral item 4.01item 9.01

  Immix Biopharma replaces auditor KMJ Corbin with Crowe LLP after KMJ partners join Crowe

  Effective July 17, 2024, Immix dismissed KMJ Corbin & Company LLP and appointed Crowe LLP as its independent registered public accounting firm.

• June 14, 2024, 7:59 PM ET other material materiality 0.45 neutral item 5.02item 5.07item 9.01

  Immix Biopharma shareholders approve 3M-share increase and evergreen provision in equity plan

  Shareholders approved increasing omnibus equity plan shares by 3,000,000 to 4,934,561 total.

• May 20, 2024, 7:59 PM ET M&A materiality 0.60 neutral item 3.02item 8.01item 9.01

  Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella

  On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

5 positive 0 negative 10 neutral

source · IMMX on sec.gov